FDA Clearance Tracker · P230032
AvertD and AvertD Buccal Sample Collection Kit
Last checked: Nov 19, 2026Latest source record: Dec 19, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Dec 19, 2023
Approved
Time to decision
85 days
Received Sep 25, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P230032
- Device name
- AvertD and AvertD Buccal Sample Collection Kit
- Applicant
- AutoGenomics, Inc.
- Applicant location
- Carlsbad, CA
- Received
- Sep 25, 2023
- Decided
- Dec 19, 2023
- Decision
- Approved
- Supplements
- 5 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
AvertD is a prescription, qualitative genotyping test used to detect and identify 15 genetic polymorphisms in genomic DNA isolated from buccal samples collected from individuals 18 years of age and older. The test may be used as part of a clinical evaluation and risk assessment to identify patients who may be at elevated risk for developing opioid use disorder (OUD). The test is indicated for use only in patients prior to receiving a first prescription of oral opioids for 4-30 days for acute pain, such as in patients scheduled to undergo a planned surgical procedure and who consent to having the test performed. The AvertD Buccal Sample Collection Kit is intended for use in the non-invasive collection, transport and storage of buccal specimens. DNA from the buccal sample will be suitable for use in AvertD. Buccal samples are collected by a qualified healthcare professional. For use only in individuals 18 years or older.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code QZH (Opioid use disorder genetic risk variant detection system and collection kit).
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
Other decisions for AutoGenomics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.